Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02). N Engl J Med 362(14): 1273-81

Impact: Health impacts, Societal impacts


Since the publication of the ABC-02 study (above, cited 894 times) the regimen of cisplatin and gemcitabine has been adopted as the standard of care chemotherapy for patients with advanced biliary tract cancer. This is reflected in the NCCN guidelines (USA), ESMO guidelines (Europe and Japan) as well as other international guidelines (e.g. ILCA).

Category of impact

  • Health impacts
  • Societal impacts